BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Vrije Universiteit Amsterdam//NONSGML v1.0//EN
NAME:PhD defence J.M. Adamska
METHOD:PUBLISH
BEGIN:VEVENT
DTSTART:20260316T134500
DTEND:20260316T151500
DTSTAMP:20260316T134500
UID:phd-defence-j-m-adamska@8F96275E-9F55-4B3F-A143-836282E12573
CREATED:20260925T004321
LOCATION:
SUMMARY:PhD defence J.M. Adamska
X-ALT-DESC;FMTTYPE=text/html: <html> <body> <p><p>When Light Meets Che
 mokine Receptors: Photocontrolling ACKR3 and CXCR4 Function</p></p> <
 p>Photopharmacology integrates photochemical principles with pharmaco
 logy to achieve light-dependent regulation of biological targets usin
 g photoswitchable molecules. Light-driven control enables temporal an
 d spatial accuracy, offering new possibilities to study dynamic signa
 ling processes while limiting undesired systemic effects.G protein-co
 upled receptors (GPCRs) represent the largest group of proteins targe
 ted by therapeutic drugs and play central roles in numerous physiolog
 ical functions. Within GPCRs, the chemokine receptors CXCR4 and ACKR3
  are critically involved in immune cell trafficking, tissue developme
 nt, inflammation, and cancer progression. However, conventional pharm
 acological tools targeting these receptors act globally and lack the 
 ability to reversibly modulate receptor activity in space and time. T
 his PhD thesis reports the development and pharmacological characteri
 zation of azobenzene-based photoswitchable ligands designed to enable
  optical control of CXCR4 and ACKR3. To support ligand discovery and 
 evaluation, chemokine receptor binding assays based on NanoBRET techn
 ology were established and expanded into a multiplexed format. Using 
 these platforms, the first photoswitchable CXCR4 antagonist was ident
 ified, alongside the first photoswitchable agonist and inverse agonis
 t for ACKR3, allowing reversible and bidirectional modulation of rece
 ptor activity with light. The compounds were characterized using mult
 iple GPCR-relevant assays, including binding studies, β-arrestin2 re
 cruitment assays, FRET-based biosensors, and fluorescence imaging of 
 ligand binding. In addition, assay formats suitable for in situ photo
 switching were assessed and adapted. Overall, this work demonstrates 
 that chemokine receptor activity can be modulated with high spatiotem
 poral precision using photoswitchable ligands. The tools and methodol
 ogies developed in this thesis expand the photopharmacological toolki
 t for GPCR research and provide new opportunities to investigate CXCR
 4 and ACKR3 signaling dynamics, with potential relevance for future l
 ight-controlled therapeutic strategies.</p><p>More information on the
  <a href="https://hdl.handle.net/1871.1/d2154334-3750-46c0-8282-dfeeb
 1c8fa21" data-new-window="true" target="_blank" rel="noopener norefer
 rer">thesis</a></p> </body> </html>
DESCRIPTION: When Light Meets Chemokine Receptors: Photocontrolling AC
 KR3 and CXCR4 Function Photopharmacology integrates photochemical pri
 nciples with pharmacology to achieve light-dependent regulation of bi
 ological targets using photoswitchable molecules. Light-driven contro
 l enables temporal and spatial accuracy, offering new possibilities t
 o study dynamic signaling processes while limiting undesired systemic
  effects.G protein-coupled receptors (GPCRs) represent the largest gr
 oup of proteins targeted by therapeutic drugs and play central roles 
 in numerous physiological functions. Within GPCRs, the chemokine rece
 ptors CXCR4 and ACKR3 are critically involved in immune cell traffick
 ing, tissue development, inflammation, and cancer progression. Howeve
 r, conventional pharmacological tools targeting these receptors act g
 lobally and lack the ability to reversibly modulate receptor activity
  in space and time. This PhD thesis reports the development and pharm
 acological characterization of azobenzene-based photoswitchable ligan
 ds designed to enable optical control of CXCR4 and ACKR3. To support 
 ligand discovery and evaluation, chemokine receptor binding assays ba
 sed on NanoBRET technology were established and expanded into a multi
 plexed format. Using these platforms, the first photoswitchable CXCR4
  antagonist was identified, alongside the first photoswitchable agoni
 st and inverse agonist for ACKR3, allowing reversible and bidirection
 al modulation of receptor activity with light. The compounds were cha
 racterized using multiple GPCR-relevant assays, including binding stu
 dies, β-arrestin2 recruitment assays, FRET-based biosensors, and flu
 orescence imaging of ligand binding. In addition, assay formats suita
 ble for in situ photoswitching were assessed and adapted. Overall, th
 is work demonstrates that chemokine receptor activity can be modulate
 d with high spatiotemporal precision using photoswitchable ligands. T
 he tools and methodologies developed in this thesis expand the photop
 harmacological toolkit for GPCR research and provide new opportunitie
 s to investigate CXCR4 and ACKR3 signaling dynamics, with potential r
 elevance for future light-controlled therapeutic strategies.More info
 rmation on the <a href="https://hdl.handle.net/1871.1/d2154334-3750-4
 6c0-8282-dfeeb1c8fa21" data-new-window="true" target="_blank" rel="no
 opener noreferrer">thesis</a>
END:VEVENT
END:VCALENDAR
